Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland

AIM: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. METHODS: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pego...

Descripción completa

Detalles Bibliográficos
Autores principales: Purmonen, Timo, Puolakka, Kari, Mishra, Dinesh, Gunda, Praveen, Martikainen, Janne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386207/
https://www.ncbi.nlm.nih.gov/pubmed/30858713
http://dx.doi.org/10.2147/CEOR.S192235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386207/
https://www.ncbi.nlm.nih.gov/pubmed/30858713
http://dx.doi.org/10.2147/CEOR.S192235

Ejemplares similares